{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:52:29Z","timestamp":1740163949772,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Forschungsnetzwerk der Universit\u00e4tsmedizin zu COVID-19","award":["COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021"],"award-info":[{"award-number":["COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021","COVIM, FKZ: 01KX2021"]}]},{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Willy Robert Pitzer Foundation"},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Establishing the optimal treatment for COVID-19 patients remains challenging. Specifically, immunocompromised and pre-diseased patients are at high risk for severe disease course and face limited therapeutic options. Convalescent plasma (CP) has been considered as therapeutic approach, but reliable data are lacking, especially for high-risk patients. We performed a retrospective analysis of 55 hospitalized COVID-19 patients from University Hospital Duesseldorf (UKD) at high risk for disease progression, in a substantial proportion due to immunosuppression from cancer, solid organ transplantation, autoimmune disease, dialysis. A matched-pairs analysis (1:4) was performed with 220 patients from the Lean European Open Survey on SARS-CoV-2-infected Patients (LEOSS) who were treated or not treated with CP. Both cohorts had high mortality (UKD 41.8%, LEOSS 34.1%). A matched-pairs analysis showed no significant effect on mortality. CP administration before the formation of pulmonary infiltrates showed the lowest mortality in both cohorts (10%), whereas mortality in the complicated phase was 27.8%. CP administration during the critical phase revealed the highest mortality: UKD 60.9%, LEOSS 48.3%. In our cohort of COVID-19 patients with severe comorbidities CP did not significantly reduce mortality in a retrospective matched-pairs analysis. However, our data supports the concept that a reduction in mortality is achievable by early CP administration.<\/jats:p>","DOI":"10.1038\/s41598-022-23200-1","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T11:02:54Z","timestamp":1667991774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1793","authenticated-orcid":false,"given":"Noemi F.","family":"Freise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smaranda","family":"Gliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lutterbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Sch\u00f6ler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"B\u00f6lke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Martin","family":"Orth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Feldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Roemmele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Isberner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pilgram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg J.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"LEOSS Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"de With","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Lanznaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"G\u00f6pel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timm","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Rothfuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegbert","family":"Rieg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Madeleine","family":"Ruethrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hanses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"unstructured":"WHO Coronavirus (COVID-19) Dashboard https:\/\/covid19.who.int [Available from 29 July 2022].","key":"23200_CR1"},{"issue":"3","key":"23200_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19(3), 141\u2013154 (2021).","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"23200_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/25787489.2021.1975608","volume":"22","author":"LK Barbera","year":"2021","unstructured":"Barbera, L. K. et al. HIV and COVID-19: review of clinical course and outcomes. HIV Res. Clin. Pract. 22(4), 102\u2013118 (2021).","journal-title":"HIV Res. Clin. Pract."},{"issue":"3","key":"23200_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jinf.2021.01.022","volume":"82","author":"JA Belsky","year":"2021","unstructured":"Belsky, J. A. et al. COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 82(3), 329\u2013338 (2021).","journal-title":"J Infect."},{"issue":"16","key":"23200_CR5","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.3390\/jcm10163595","volume":"10","author":"M Martinez-Urbistondo","year":"2021","unstructured":"Martinez-Urbistondo, M. et al. Severe lymphopenia as a predictor of COVID-19 mortality in immunosuppressed patients. J. Clin. Med. 10(16), 3595 (2021).","journal-title":"J. Clin. Med."},{"issue":"19","key":"23200_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of covid-19 - final report. N. Engl. J. Med. 383(19), 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"unstructured":"FDA. Convalescent Plasma EUA Letter of Authorization 12282021. FDA; 2020 [25 January 2022]. Available from: https:\/\/www.fda.gov\/media\/141477\/download.","key":"23200_CR7"},{"issue":"3","key":"23200_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 384(3), 238\u2013251 (2021).","journal-title":"N Engl J Med."},{"issue":"8","key":"23200_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann. Intern. Med. 145(8), 599\u2013609 (2006).","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"23200_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.2020.10218","volume":"324","author":"A Casadevall","year":"2020","unstructured":"Casadevall, A., Joyner, M. J. & Pirofski, L. A. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA 324(5), 455\u2013457 (2020).","journal-title":"JAMA"},{"issue":"7","key":"23200_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41577-020-0365-7","volume":"20","author":"J Abraham","year":"2020","unstructured":"Abraham, J. Passive antibody therapy in COVID-19. Nat. Rev. Immunol. 20(7), 401\u2013403 (2020).","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"23200_CR12","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.jaip.2020.06.046","volume":"8","author":"E Mira","year":"2020","unstructured":"Mira, E. et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J. Allergy Clin. Immunol. Pract. 8(8), 2793\u20132795 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"7","key":"23200_CR13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"VA Avanzato","year":"2020","unstructured":"Avanzato, V. A. et al. Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183(7), 1901\u20131912 (2020).","journal-title":"Cell"},{"issue":"4","key":"23200_CR14","doi-asserted-by":"publisher","first-page":"e0048021","DOI":"10.1128\/mSphere.00480-21","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. mSphere. 6(4), e0048021 (2021).","journal-title":"mSphere."},{"issue":"17","key":"23200_CR15","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. U S A. 117(17), 9490\u20139496 (2020).","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"5","key":"23200_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA 324(5), 460\u2013470 (2020).","journal-title":"JAMA"},{"issue":"7853","key":"23200_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592(7853), 277\u2013282 (2021).","journal-title":"Nature"},{"issue":"5","key":"23200_CR18","first-page":"1262","volume":"96","author":"SA Klassen","year":"2021","unstructured":"Klassen, S. A. et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: Systematic review and meta-analysis. medRxiv. 96(5), 1262\u20131275 (2021).","journal-title":"medRxiv."},{"key":"23200_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645989","volume":"12","author":"V Keitel","year":"2021","unstructured":"Keitel, V. et al. Case report: Convalescent plasma achieves SARS-CoV-2 viral clearance in a patient with persistently high viral replication over 8 weeks due to severe combined immunodeficiency (SCID) and graft failure. Front. Immunol. 12, 645989 (2021).","journal-title":"Front. Immunol."},{"key":"23200_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2021.100096","volume":"12","author":"G Casarola","year":"2021","unstructured":"Casarola, G. et al. Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report. Clin. Infect Pract. 12, 100096 (2021).","journal-title":"Clin. Infect Pract."},{"issue":"20","key":"23200_CR21","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","volume":"136","author":"T Hueso","year":"2020","unstructured":"Hueso, T. et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 136(20), 2290\u20132295 (2020).","journal-title":"Blood"},{"issue":"4","key":"23200_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00030-6","volume":"2","author":"RN Rodionov","year":"2021","unstructured":"Rodionov, R. N. et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe. 2(4), e138 (2021).","journal-title":"Lancet Microbe."},{"issue":"8","key":"23200_CR23","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.16525","volume":"61","author":"JW Senefeld","year":"2021","unstructured":"Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 61(8), 2503\u20132511 (2021).","journal-title":"Transfusion"},{"unstructured":"Sekine, L. et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur. Respir J. 2021.","key":"23200_CR24"},{"issue":"3","key":"23200_CR25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/jmv.26533","volume":"93","author":"SR Nagarakanti","year":"2021","unstructured":"Nagarakanti, S. R., Okoh, A. K., Grinberg, S. & Bishburg, E. Clinical outcomes of patients with COVID-19 and HIV coinfection. J. Med. Virol. 93(3), 1687\u20131693 (2021).","journal-title":"J. Med. Virol."},{"issue":"8","key":"23200_CR26","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1016\/S2352-3018(20)30163-6","volume":"7","author":"Z Xu","year":"2020","unstructured":"Xu, Z., Zhang, C. & Wang, F. S. COVID-19 in people with HIV. Lancet HIV. 7(8), e524\u2013e526 (2020).","journal-title":"Lancet HIV."},{"issue":"9","key":"23200_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","volume":"8","author":"C Karagiannidis","year":"2020","unstructured":"Karagiannidis, C. et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: An observational study. Lancet Respir. Med. 8(9), 853\u2013862 (2020).","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"23200_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","volume":"10","author":"V Mehta","year":"2020","unstructured":"Mehta, V. et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 10(7), 935\u2013941 (2020).","journal-title":"Cancer Discov."},{"issue":"25","key":"23200_CR29","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMc2011117","volume":"382","author":"E Akalin","year":"2020","unstructured":"Akalin, E. et al. Covid-19 and kidney transplantation. N. Engl. J. Med. 382(25), 2475\u20132477 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"23200_CR30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.kint.2020.04.002","volume":"97","author":"F Alberici","year":"2020","unstructured":"Alberici, F. et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 97(6), 1083\u20131088 (2020).","journal-title":"Kidney Int."},{"issue":"12","key":"23200_CR31","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1002\/jmv.27271","volume":"93","author":"G Yilmaz","year":"2021","unstructured":"Yilmaz, G., Ebru, O., Ibrahim, B. & Ulkem, C. Assessment of clinical outcomes in renal transplant recipients with COVID-19. J. Med. Virol. 93(12), 6760\u20136764 (2021).","journal-title":"J. Med. Virol."},{"issue":"5","key":"23200_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/BOR.0000000000000822","volume":"33","author":"P Mehta","year":"2021","unstructured":"Mehta, P. & Fajgenbaum, D. C. Is severe COVID-19 a cytokine storm syndrome: A hyperinflammatory debate. Curr. Opin. Rheumatol. 33(5), 419\u2013430 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"23200_CR33","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.jinf.2020.04.026","volume":"81","author":"C Minotti","year":"2020","unstructured":"Minotti, C., Tirelli, F., Barbieri, E., Giaquinto, C. & Dona, D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J. Infect. 81(1), e61\u2013e66 (2020).","journal-title":"J. Infect."},{"issue":"11","key":"23200_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","volume":"384","author":"MJ Joyner","year":"2021","unstructured":"Joyner, M. J. et al. Convalescent plasma antibody levels and the risk of death from covid-19. N. Engl. J. Med. 384(11), 1015\u20131027 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"23200_CR35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","volume":"384","author":"R Libster","year":"2021","unstructured":"Libster, R. et al. Early High-titer plasma therapy to prevent severe covid-19 in older adults. N. Engl. J. Med. 384(7), 610\u2013618 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"23200_CR36","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/j.ajpath.2020.08.001","volume":"190","author":"E Salazar","year":"2020","unstructured":"Salazar, E. et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am. J. Pathol. 190(11), 2290\u20132303 (2020).","journal-title":"Am. J. Pathol."},{"unstructured":"World Health O. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 12 January 2020. Geneva: World Health Organization; 2020. Contract No.: WHO\/2019-nCoV\/Clinical\/2020.1.","key":"23200_CR37"},{"issue":"4","key":"23200_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.6002\/ect.2020.0479","volume":"19","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Feasibility of convalescent plasma therapy in kidney transplant recipients with severe COVID-19: A single-center prospective cohort study. Exp. Clin. Transpl. 19(4), 304\u2013309 (2021).","journal-title":"Exp. Clin. Transpl."},{"issue":"12","key":"23200_CR39","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/jama.2021.2747","volume":"325","author":"P Janiaud","year":"2021","unstructured":"Janiaud, P. et al. Association of convalescent plasma treatment with clinical outcomes in patients With COVID-19: A systematic review and meta-analysis. JAMA 325(12), 1185\u20131195 (2021).","journal-title":"JAMA"},{"issue":"1","key":"23200_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/trf.16177","volume":"61","author":"FT Nguyen","year":"2021","unstructured":"Nguyen, F. T. et al. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. Transfusion 61(1), 78\u201393 (2021).","journal-title":"Transfusion"},{"key":"23200_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100164","volume":"8","author":"B Jensen","year":"2021","unstructured":"Jensen, B. et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg. Health Eur. 8, 100164 (2021).","journal-title":"Lancet Reg. Health Eur."},{"issue":"8","key":"23200_CR42","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/v13081642","volume":"13","author":"N Peiffer-Smadja","year":"2021","unstructured":"Peiffer-Smadja, N. et al. Emergence of E484K mutation following bamlanivimab monotherapy among high-risk patients infected with the alpha variant of SARS-CoV-2. Viruses 13(8), 1642 (2021).","journal-title":"Viruses"},{"issue":"7","key":"23200_CR43","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00392-020-01769-9","volume":"110","author":"S Cremer","year":"2021","unstructured":"Cremer, S. et al. Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: Insights from the LEOSS registry. Clin. Res. Cardiol. 110(7), 1029\u20131040 (2021).","journal-title":"Clin. Res. Cardiol."},{"issue":"3","key":"23200_CR44","doi-asserted-by":"publisher","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","volume":"25","author":"VM Corman","year":"2020","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25(3), 2000045 (2020).","journal-title":"Euro Surveill."},{"key":"23200_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104579","volume":"130","author":"N Lubke","year":"2020","unstructured":"Lubke, N. et al. Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 130, 104579 (2020).","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"unstructured":"Elecsys Anti-SARS-COV2-factsheet 2020, July [Available from: https:\/\/diagnostics.roche.com\/global\/en\/products\/params\/elecsys-anti-sars-cov-2.html. Elecsys Anti-SARS-COV2-factsheet. Juli 2020.pdf.","key":"23200_CR46"},{"issue":"8","key":"23200_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho, D. E., King, G. & Stuart, E. A. MatchIt: Nonparametric preprocessing for parametric causal inference. J. Stat. Softw. 42(8), 1\u201328 (2011).","journal-title":"J. Stat. Softw."},{"unstructured":"Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria2020 [17 february 2022]. Available from: https:\/\/www.R-project.org\/.","key":"23200_CR48"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23200-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23200-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23200-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T20:00:44Z","timestamp":1728331244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23200-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23200"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23200-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19035"}}